Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. TRIN
TRIN logo

TRIN Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
15.020
Open
14.980
VWAP
14.84
Vol
1.14M
Mkt Cap
1.24B
Low
14.700
Amount
16.93M
EV/EBITDA(TTM)
11.63
Total Shares
83.17M
EV
2.51B
EV/OCF(TTM)
--
P/S(TTM)
3.62
Trinity Capital Inc. is an internally managed, closed-end, non-diversified management investment company that operates as a business development company. It is a specialty lending company that provides debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its investment objective is to generate current income and capital appreciation through its investments across five vertical markets. It seeks to achieve its investment objective by making investments consisting primarily of term loans and equipment financings and working capital loans, equity and equity-related investments. Its equipment financings involve loans for general or specific use, including acquiring equipment that is secured by the equipment or other assets of the portfolio company. It targets investments in growth-stage companies that are typically private companies, including institutional investor-based companies.
Show More

Events Timeline

(ET)
2026-03-11
08:10:00
Emboline Closes $20M Growth Capital
select
2026-03-10 (ET)
2026-03-10
08:10:00
Trinity Capital Commits $35M to Neuros Medical
select
2026-02-25 (ET)
2026-02-25
08:10:00
Trinity Capital Reports Q4 Revenue of $83.2M, NAV Up 32.9%
select
2026-02-03 (ET)
2026-02-03
08:10:00
Sees Q4 NAV per Share as $13.36-$13.44 by December 31, 2025
select
2025-12-17 (ET)
2025-12-17
16:10:00
Trinity Capital Announces Monthly Dividends of 17 Cents Starting January 2026
select
2025-12-04 (ET)
2025-12-04
08:20:00
Trinity Capital Commits Equipment Financing to Sortera Technologies
select

News

Newsfilter
8.5
12:40 PMNewsfilter
PinnedEmboline Secures $20 Million Growth Capital for Stroke Prevention Technology
  • Funding for Commercialization: Emboline has successfully secured $20 million in growth capital, which will support upcoming commercial launch activities and the continued development of its embolic protection technology platform, significantly enhancing its market competitiveness.
  • Clinical Trial Progress: Emboline recently completed enrollment in the PROTECT H2H clinical trial, aimed at evaluating the efficacy of the Emboliner® Embolic Protection System, with results to be presented on March 29, 2026, at the American College of Cardiology Annual Scientific Session, potentially providing crucial data for clinical application.
  • Innovative Technology Goals: The Emboliner® system is designed to provide comprehensive cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures, which will help reduce the risk of stroke and other embolic complications, thereby enhancing interventional cardiologists' confidence.
  • Strategic Partnership: The collaboration with Trinity Capital lays the groundwork for Emboline's commercial launch in the U.S. and Europe, indicating the company's strategic decisions in technology development and market promotion to meet the growing global demand for cardiovascular intervention technologies.
seekingalpha
8.5
14:12 PMseekingalpha
Trinity Capital Commits $20 Million to Emboline for Growth Capital
  • Funding Commitment: Trinity Capital has announced a $20 million investment in medical technology company Emboline to support the commercial launch of its Emboliner embolic protection catheter, aimed at reducing the risk of strokes and other complications during minimally invasive heart procedures.
  • Clinical Trial Progress: Emboline has recently completed patient enrollment in the PROTECT H2H investigational device exemption clinical trial, which is crucial for generating the data needed for regulatory approval, indicating the company's proactive steps towards product commercialization.
  • Manufacturing Expansion: This financing will enable Emboline to scale its manufacturing capabilities, expand its team, and support clinical and regulatory milestones, thereby laying a solid foundation for the successful launch of its product.
  • Market Outlook: Trinity Capital's investment not only reflects confidence in Emboline's technology but also indicates a strategic positioning in the medical device sector, which is expected to enhance the company's competitiveness in the rapidly growing healthcare market.
PRnewswire
8.5
12:55 PMPRnewswire
Emboline Secures $20 Million Growth Capital for Stroke Prevention Technology
  • Funding for Commercialization: Emboline has successfully secured $20 million in growth capital, which will support its upcoming commercial launch activities and the continued development of its embolic protection technology platform, thereby enhancing its competitive position in the structural heart surgery market.
  • Clinical Trial Progress: Emboline recently completed enrollment in the PROTECT H2H clinical trial, aimed at evaluating the efficacy of the Emboliner® Embolic Protection System, with results expected to be presented on March 29, 2026, at the American College of Cardiology Annual Scientific Session, further validating its technology's clinical application potential.
  • Innovation Goals: The Emboliner® system is designed to provide comprehensive cerebral and systemic embolic protection by capturing and removing embolic debris released during transcatheter heart procedures, thus reducing the risk of stroke and other embolic complications while enhancing interventional cardiologists' confidence in complex procedures.
  • Intellectual Property Advantage: Emboline holds an extensive intellectual property portfolio related to aortic embolic protection technologies, including full-body embolic filtration and aortic deflection methods, which lays a solid foundation for future technology development and market expansion.
Newsfilter
7.5
12:41 PMNewsfilter
Trinity Capital Commits $20 Million to Emboline for Growth Capital
  • Investment Amount: Trinity Capital has announced a $20 million investment in MedTech company Emboline to support the development of technologies aimed at reducing strokes and other complications during heart procedures, demonstrating strong support for medical innovation.
  • Product Innovation: Emboline's Emboliner® Embolic Protection Catheter features a flexible mesh design that captures and removes debris that could lead to strokes while allowing normal blood flow, significantly enhancing the safety of minimally invasive procedures.
  • Clinical Trial Progress: Emboline recently completed patient enrollment in the PROTECT H2H investigational device exemption (IDE) clinical trial, aiming to generate the necessary clinical data for regulatory approval and commercial launch, marking a significant step towards bringing new technology to market.
  • Strategic Partnership: The financing from Trinity Capital will strengthen Emboline's manufacturing capabilities and team expansion, supporting the achievement of clinical and regulatory milestones that will drive the global commercialization of the Emboliner system.
seekingalpha
7.5
03-10seekingalpha
Trinity Capital Commits $35 Million to Neuros Medical for Growth
  • Capital Commitment: Trinity Capital announced a $35 million investment in Neuros Medical to support the expansion and commercialization of its Altius Direct Electrical Nerve Stimulation System, aimed at alleviating chronic post-amputation pain, highlighting its commitment to medical innovation.
  • Market Expansion: This financing will assist Neuros Medical in scaling the adoption of its therapy and support entry into new markets, thereby enhancing the company's competitiveness in the medical device sector.
  • Investment Return Potential: Trinity Capital's investment not only provides essential funding for Neuros Medical but also has the potential to yield significant returns through successful market penetration, improving the overall financial performance of the firm.
  • Industry Outlook: With the rising demand for chronic pain management solutions, this investment reflects confidence in medical technology innovation, potentially offering Trinity Capital long-term strategic benefits and market share growth.
seekingalpha
9.5
02-25seekingalpha
Trinity Capital Reports Record Earnings and Strategic Growth in Q4 2025
  • Record Investment Income: Trinity Capital achieved a record net investment income of $144 million in 2025, reflecting significant growth across major operating categories and showcasing the company's strong financial performance and market competitiveness.
  • Net Asset Value Growth: The company's net asset value increased from $998 million to $1.1 billion in Q4, representing a 10% quarter-over-quarter growth, which underscores successful capital raising and investment strategies that enhance its market position.
  • Diversified Portfolio: Trinity Capital's portfolio spans 22 industries with no single borrower exceeding 3.9% of total exposure, demonstrating exceptional risk management capabilities that ensure stability and resilience in uncertain market conditions.
  • Robust Investment Pipeline: As of year-end, the company reported $1.2 billion in total unfunded commitments, with 93% of these commitments subject to rigorous ongoing diligence and investment committee approval, indicating a cautious and strategic approach to future investment opportunities.
Wall Street analysts forecast TRIN stock price to rise
6 Analyst Rating
Wall Street analysts forecast TRIN stock price to rise
5 Buy
0 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
13.50
Averages
16.50
High
17.50
Current: 0.000
sliders
Low
13.50
Averages
16.50
High
17.50
Clear Street
Mickey Schleien
Buy
initiated
$18
AI Analysis
2026-02-04
Reason
Clear Street
Mickey Schleien
Price Target
$18
AI Analysis
2026-02-04
initiated
Buy
Reason
Clear Street analyst Mickey Schleien initiated coverage of Trinity Capital with a Buy rating and $18 price target. In the internally managed business development company universe, the firm sees Trinity combining strong portfolio yields, solid dividend coverage, and emerging fee-based earnings optionality and trading at a discount to peers, the analyst tells investors.
Citizens
Outperform
maintain
$19
2026-01-27
Reason
Citizens
Price Target
$19
2026-01-27
maintain
Outperform
Reason
Citizens raised the firm's price target on Trinity Capital to $19 from $17.50 and keeps an Outperform rating on the shares. The private capital industry is adjusting to a new operating backdrop marked by lower interest rates, creating mixed impacts across products but underscoring the importance of understanding underlying earnings drivers, the analyst tells investors in a research note. Scale and diversification should support resilient growth into 2026, making manager selection increasingly critical despite expectations for continued industry expansion, the firm says.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TRIN
Unlock Now

Valuation Metrics

The current forward P/E ratio for Trinity Capital Inc (TRIN.O) is 7.24, compared to its 5-year average forward P/E of 7.45. For a more detailed relative valuation and DCF analysis to assess Trinity Capital Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
7.45
Current PE
7.24
Overvalued PE
8.79
Undervalued PE
6.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.48
Current PS
3.43
Overvalued PS
4.19
Undervalued PS
2.77

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

top financial stocks to buy under 20 bucks
Intellectia · 14 candidates
Market Cap: >= 1000.00MSector: FinancialsPrice: $3.00 - $20.00Analyst Consensus: Strong Buy, Moderate BuyList Exchange: XNYS, XNAS, XASEReturn On Equity: >= 8.0%One Week Rise Prob: >= 0One Month Predict Return: >= 0.0%
Ticker
Name
Market Cap$
top bottom
ITUB logo
ITUB
Itau Unibanco Holding SA
101.11B
BBD logo
BBD
Banco Bradesco SA
41.67B
QFIN logo
QFIN
Qfin Holdings Inc
2.05B
NU logo
NU
Nu Holdings Ltd
81.50B
GBDC logo
GBDC
Golub Capital BDC Inc
3.22B
XP logo
XP
XP Inc
10.21B
swing trade
Intellectia · 36 candidates
Price: $10.00 - $100.00Rsi Category: moderateNew High Low: 52w_HighMoving Average Relationship: PriceAboveMA20, PriceAboveMA200Monthly Average Dollar Volume: >= 1,500,000
Ticker
Name
Market Cap$
top bottom
VIAV logo
VIAV
Viavi Solutions Inc
4.55B
DOLE logo
DOLE
Dole PLC
1.47B
ARRY logo
ARRY
Array Technologies Inc
1.70B
NG logo
NG
NovaGold Resources Inc
4.52B
KNSA logo
KNSA
Kiniksa Pharmaceuticals International PLC
3.35B
ING logo
ING
ING Groep NV
87.27B
quickest dividend yield stocks
Intellectia · 75 candidates
Dividend Yield Ttm: >= 5Dividend Payout Ratio: 50.00 - 100.00
Ticker
Name
Market Cap$
top bottom
RWAY logo
RWAY
Runway Growth Finance Corp
338.21M
NREF logo
NREF
Nexpoint Real Estate Finance Inc
260.69M
TRIN logo
TRIN
Trinity Capital Inc
1.25B
TSQ logo
TSQ
Townsquare Media Inc
94.15M
GBDC logo
GBDC
Golub Capital BDC Inc
3.64B
GLAD logo
GLAD
Gladstone Capital Corp
475.81M
i have 19 what stock can help me right now
Intellectia · 13 candidates
Dividend Yield Ttm: >= 2Price: <= $19.00Beta: LowRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 20Annual Revenue Yoy Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
ABEV logo
ABEV
Ambev SA
41.38B
BBD logo
BBD
Banco Bradesco SA
39.45B
DOC logo
DOC
Healthpeak Properties Inc
12.45B
GBDC logo
GBDC
Golub Capital BDC Inc
3.64B
KRP logo
KRP
Kimbell Royalty Partners LP
1.36B
TRIN logo
TRIN
Trinity Capital Inc
1.25B
Market cap below 10 billion
Intellectia · 22 candidates
Market Cap: <= 10.00BNet Margin: >= 10.00Beta: LowRiskWeekly Average Turnover: >= 1,000,000Pe Ttm: <= 15Annual Revenue Yoy Growth: >= 20.0%
Ticker
Name
Market Cap$
top bottom
HALO logo
HALO
Halozyme Therapeutics Inc
8.43B
CALM logo
CALM
Cal-Maine Foods Inc
3.79B
GBDC logo
GBDC
Golub Capital BDC Inc
3.64B
HG logo
HG
Hamilton Insurance Group Ltd
2.67B
HCI logo
HCI
Hci Group Inc
2.20B
SKWD logo
SKWD
Skyward Specialty Insurance Group Inc
2.00B
what are the most undervalued stocks?
Intellectia · 14 candidates
Dividend Yield Ttm: >= 4Weekly Average Turnover: >= 1,000,000Pe Ttm: <= 7Return On Equity: >= 12.0%P Fcf Ratio: <= 7.00
Ticker
Name
Market Cap$
top bottom
PBR logo
PBR
Petroleo Brasileiro SA Petrobras
87.06B
PBR.A logo
PBR.A
Petroleo Brasileiro SA Petrobras
81.46B
EC logo
EC
Ecopetrol SA
26.42B
APA logo
APA
APA Corp (US)
9.41B
LNC logo
LNC
Lincoln National Corp
7.80B
CALM logo
CALM
Cal-Maine Foods Inc
3.79B
stocks with highest divident
Intellectia · 1646 candidates
Market Cap: >= 50.00MDividend Yield Ttm: >= 0Weekly Average Turnover: >= 1,000,000Dividend Payout Ratio: <= 100.00
Ticker
Name
Market Cap$
top bottom
TIGO logo
TIGO
Millicom International Cellular SA
9.96B
RWAY logo
RWAY
Runway Growth Finance Corp
338.21M
TRIN logo
TRIN
Trinity Capital Inc
1.25B
WU logo
WU
Western Union Co
2.95B
GBDC logo
GBDC
Golub Capital BDC Inc
3.64B
GLAD logo
GLAD
Gladstone Capital Corp
475.81M

Whales Holding TRIN

S
Sound Income Strategies, LLC
Holding
TRIN
-6.75%
3M Return
A
Ares Management LLC
Holding
TRIN
-14.17%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Trinity Capital Inc (TRIN) stock price today?

The current price of TRIN is 14.8 USD — it has decreased -0.6

What is Trinity Capital Inc (TRIN)'s business?

Trinity Capital Inc. is an internally managed, closed-end, non-diversified management investment company that operates as a business development company. It is a specialty lending company that provides debt, including loans and equipment financings, to growth-stage companies, including venture-backed companies and companies with institutional equity investors. Its investment objective is to generate current income and capital appreciation through its investments across five vertical markets. It seeks to achieve its investment objective by making investments consisting primarily of term loans and equipment financings and working capital loans, equity and equity-related investments. Its equipment financings involve loans for general or specific use, including acquiring equipment that is secured by the equipment or other assets of the portfolio company. It targets investments in growth-stage companies that are typically private companies, including institutional investor-based companies.

What is the price predicton of TRIN Stock?

Wall Street analysts forecast TRIN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TRIN is16.50 USD with a low forecast of 13.50 USD and a high forecast of 17.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Trinity Capital Inc (TRIN)'s revenue for the last quarter?

Trinity Capital Inc revenue for the last quarter amounts to 82.77M USD, increased 0.81

What is Trinity Capital Inc (TRIN)'s earnings per share (EPS) for the last quarter?

Trinity Capital Inc. EPS for the last quarter amounts to 0.51 USD, decreased -29.17

How many employees does Trinity Capital Inc (TRIN). have?

Trinity Capital Inc (TRIN) has 106 emplpoyees as of March 11 2026.

What is Trinity Capital Inc (TRIN) market cap?

Today TRIN has the market capitalization of 1.24B USD.